切换至 "中华医学电子期刊资源库"

中华关节外科杂志(电子版) ›› 2022, Vol. 16 ›› Issue (02) : 190 -195. doi: 10.3877/cma.j.issn.1674-134X.2022.02.008

综述

利奈唑胺骨水泥在关节置换感染中的应用进展
孙长鲛1, 马琦1, 房立业1, 许平平1, 李慧敏1, 蔡谞1,()   
  1. 1. 102218 清华大学附属北京清华长庚医院,清华大学临床医学院
  • 收稿日期:2020-06-08 出版日期:2022-04-01
  • 通信作者: 蔡谞
  • 基金资助:
    福建省卫生教育联合攻关项目(2019-WJ-01)

Application of linezolid bone cement in periprosthetic joint infection

Changjiao Sun1, Qi Ma1, Liye Fang1, Pingping Xu1, Huimin Li1, Xu Cai1,()   

  1. 1. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
  • Received:2020-06-08 Published:2022-04-01
  • Corresponding author: Xu Cai
引用本文:

孙长鲛, 马琦, 房立业, 许平平, 李慧敏, 蔡谞. 利奈唑胺骨水泥在关节置换感染中的应用进展[J/OL]. 中华关节外科杂志(电子版), 2022, 16(02): 190-195.

Changjiao Sun, Qi Ma, Liye Fang, Pingping Xu, Huimin Li, Xu Cai. Application of linezolid bone cement in periprosthetic joint infection[J/OL]. Chinese Journal of Joint Surgery(Electronic Edition), 2022, 16(02): 190-195.

使用抗生素骨水泥占位器的二期翻修一直是治疗假体周围感染的金标准。目前常用的添加到骨水泥中的抗生素包括庆大霉素,妥布霉素和万古霉素。但是目前对这几种抗生素耐药的细菌越来越多,因此需要除了氨基糖苷类和糖肽类以外的药物来治疗和预防假体周围感染,利奈唑胺是一个理想药物,它对革兰氏阳性病原体有高度抗菌活性,对骨骼的渗透性能好,并对生物膜中的活跃生长和静止期病原体均有抗菌活性,利奈唑胺对产生生物膜的葡萄球菌显示出与万古霉素相似或更高的疗效。这些特点对于假体周围感染的治疗至关重要。本文对利奈唑胺骨水泥在关节置换术感染中的应用进展进行综述。

Two-stage revision with antibiotic bone cement spacer has been the gold standard for the treatment of periprosthetic joint infections. Now, the most commonly used antibiotics added to bone cement include gentamicin, tobramycin and vancomycin. However, there are more and more bacteria resistant to these antibiotics. Therefore, drugs other than aminoglycosides and glycopeptides are needed to treat and prevent periprosthetic joint infections. Linezolid is an ideal drug. It has high antibacterial activity to Gram-positive pathogens, which also have good permeability to joint and bones. Linezolid has antibacterial activity against active growth and resting pathogens in biofilms which is very important for treatment of periprosthetic joint infections. Linezolid shows similar or higher efficacy to vancomycin, against staphylococcus producing biofilms. This article reviewed the progress of linezolid bone cement in periprosthetic joint infections.

[1]
Kamath AF, Ong KL, Lau E, et al. Quantifying the burden of revision total joint arthroplasty for periprosthetic infection[J]. J Arthroplasty, 2015, 30(9): 1492-1497.
[2]
张倜,郑充,马海洋,等.髋关节置换术早期失败的原因分析[J].中华医学杂志201494(48):3836-3838.
[3]
张倜,郑充,马海洋,等.髋关节置换中期失败的原因分析[J].中华医学杂志201595(3):214-216.
[4]
黄自强,孙长鲛.膝关节置换患者手术失败原因的分析[J].中华医学杂志201595(20):1606-1608.
[5]
Izakovicova P, Borens O, Trampuz A. Periprosthetic joint infection: current concepts and outlook[J]. EFORT Open Rev, 2019, 4(7): 482-494.
[6]
Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States[J]. J Arthroplasty, 2012, 27(8 Suppl): 61-65.e1.
[7]
Akindolire J, Morcos MW, Marsh JD, et al. The economic impact of periprosthetic infection in total hip arthroplasty[J]. Can J Surg, 2020, 63(1): E52-E56.
[8]
Engesaeter LB, Espehaug B, Sa L, et al. Does cement increase the risk of infection in primary total hip arthroplasty? Revision rates in 56,275 cemented and uncemented primary THAs followed for 0-16 years in the Norwegian Arthroplasty Register[J]. Acta Orthop, 2006, 77(3): 351-358.
[9]
Parvizi J, Saleh KJ, Ragland PS, et al. Efficacy of antibiotic-impregnated cement in total hip replacement[J]. Acta Orthop, 2008, 79(3): 335-341.
[10]
Anagnostakos K. Therapeutic use of antibiotic-loaded bone cement in the treatment of hip and knee joint infections[J]. J Bone Jt Infect, 2017, 2(1): 29-37.
[11]
Cui Q, Wm M, Shields JS, et al. Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty[J]. J Bone Joint Surg Am, 2007, 89(4): 871-882.
[12]
System N. National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. A report from the NNIS system[J]. Am J Infect Control, 1999, 27(6): 520-532.
[13]
Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991[J]. Infect Control Hosp Epidemiol, 1992, 13(10): 582-586.
[14]
Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003[J]. Clin Infect Dis, 2006, 42(3): 389-391.
[15]
Sawada M, Oe K, Hirata M, et al. Linezolid versus daptomycin treatment for periprosthetic joint infections: a retrospective cohort study[J]. J Orthop Surg Res, 2019, 14(1): 334-341.
[16]
孙长鲛,周勇刚,柴伟,等.髋关节置换术后感染的微生物特点及药敏分析[J].中华医学杂志201494(21):1657-1660.
[17]
孙长鲛,柴伟,潘勇卫,等.膝关节置换术后感染的微生物学及药敏分析[J].中华医学杂志201494(45):3575-3578.
[18]
Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections[J]. N Engl J Med, 2004, 351(16): 1645-1654.
[19]
Shahpari O, Mousavian A, Elahpour N, et al. The use of antibiotic impregnated cement spacers in the treatment of infected total joint replacement: challenges and achievements[J]. Arch Bone Jt Surg, 2020, 8(1): 11-20.
[20]
孙长鲛,周勇刚.抗菌药物骨水泥在关节置换术中的研究进展[J].中华医院感染学杂志201222(12):2711-2714.
[21]
孙长鲛,周勇刚.关节置换术后耐甲氧西林金黄色葡萄球菌感染的研究进展[J].中华医院感染学杂志201424(12):3118-3120.
[22]
Hendriks JG, Van Horn JR, Van Der Mei HC, et al. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection[J]. Biomaterials, 2004, 25(3): 545-556.
[23]
Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms[J]. Int J Med Microbiol, 2002, 292(2): 107-113.
[24]
Hope PG, Kristinsson KG, Norman P, et al. Deep infection of cemented total hip arthroplasties caused by coagulase-negatives taphylococci[J]. J Bone Joint Surg Br, 1989, 71(5): 851-855.
[25]
Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach[J]. J Antimicrob Chemother, 2009, 63(2): 246-251.
[26]
Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J]. Pharmacotherapy, 2009, 29(11): 1275-1279.
[27]
Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections[J]. Clin Infect Dis, 2007, 45 Suppl 3: S191-S195.
[28]
Cacciola G, De Meo F, Cavaliere P. Mechanical and elution properties of G3 Low Viscosity bone cement loaded up to three antibiotics[J]. J Orthop, 2018, 15(4): 1004-1007.
[29]
Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity[J]. Arch Intern Med, 2006, 166(19): 2138-2144.
[30]
Haddad FS, Masri BA, Campbell D, et al. The PROSTALAC functional spacer in two-stage revision for infected knee replacements. Prosthesis of antibiotic-loaded acrylic cement[J]. J Bone Joint Surg Br, 2000, 82(6): 807-812.
[31]
Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)[J]. Diagn Microbiol Infect Dis, 2008, 61(2): 235-239.
[32]
Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period[J]. J Clin Microbiol, 2006, 44(11): 3883-3886.
[33]
Richelsoph KC, Webb ND, Haggard WO. Elution behavior of daptomycin-loaded calcium sulfate pellets: a preliminary study[J]. Clin Orthop Relat Res, 2007, 461: 68-73.
[34]
Rouse MS, Piper KE, Jacobson M, et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis[J]. J Antimicrob Chemother, 2006, 57(2): 301-305.
[35]
Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J]. Clin Infect Dis, 2001, 32 Suppl 2: S114-132.
[36]
Akins RL, Haase KK. Gram-positive resistance:pathogens,implications,and treatment options:insights from the Society of Infectious Diseases Pharmacists[J]. Pharmacotherapy, 2005, 25(7): 1001-1010.
[37]
Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus[J]. Clin Microbiol Infect, 2006, 12(Suppl 1): 16-23.
[38]
Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them[J]. Perit Dial Int, 2005, 25(4): 313-319.
[39]
Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications[J]. Clin Microbiol Rev, 2010, 23(1): 99-139.
[40]
Adams B, Roboubi B, Henshaw R. Acute onset of vancomycin anaphylaxis with disseminated intravascular coagulation in an orthopedic patient despite prior repeated exposure[J]. Am J Orthop (Belle Mead NJ), 2015, 44(12): E523-E525.
[41]
Cobo J, Miguel LG, Euba G, et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy[J]. Clin Microbiol Infect, 2011, 17(11): 1632-1637.
[42]
Lourtet-Hascoët J, Félicé MP, Bicart-See A, et al. Species and antimicrobial susceptibility testing of coagulase-negative staphylococci in periprosthetic joint infections[J]. Epidemiol Infect, 2018, 146(14): 1771-1776.
[43]
Eriksson HK, Ahadpour D, Hailer NP, et al. Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci[J]. Infect Dis (Lond), 2019, 51(9): 683-690.
[44]
Armstrong MS, Spencer RF, Cunningham JL, et al. Mechanical characteristics of antibiotic-laden bone cement[J]. Acta Orthop Scand, 2002, 73(6): 688-690.
[45]
Gálvez-López R, Peña-Monje A, Antelo-Lorenzo R, et al. Elution kinetics, antimicrobial activity, and mechanical properties of 11 different antibiotic loaded acrylic bone cement[J]. Diagn Microbiol Infect Dis, 2014, 78(1): 70-74.
[46]
Joseph TN, Chen AL, Di Cesare PE. Use of antibiotic-impregnated cement in total joint arthroplasty[J]. J Am Acad Orthop Surg, 2003, 11(1): 38-47.
[47]
Paz E, Sanz-Ruiz P, Abenojar J, et al. Evaluation of elution and mechanical properties of high-dose antibiotic-loaded bone cement: comparative " in vitro" study of the influence of vancomycin and cefazolin[J]. J Arthroplasty, 2015, 30(8): 1423-1429.
[48]
Fink B, Vogt S, Reinsch M, et al. Sufficient release of antibiotic by a spacer 6 weeks after implantation in two-stage revision of infected hip prostheses[J]. Clin Orthop Relat Res, 2011, 469(11): 3141-3147.
[49]
孙长鲛,柴伟,潘勇卫,等. 利奈唑胺骨水泥在关节置换术后感染治疗中应用的系列探索研究之一——利奈唑胺骨水泥的物理、力学性能研究[J/CD]. 中华关节外科杂志(电子版), 20148(3):55-58.
[50]
Azuara G, García-García J, Ibarra B, et al. Experimental study of the application of a new bone cement loaded with broad spectrum antibiotics for the treatment of bone infection[J]. Rev Esp Cir Ortop Traumatol, 2019, 63(2): 95-103.
[51]
Anguita-Alonso P, Rouse MS, Piper KE, et al. Comparative study of antimicrobial release kinetics from polymethylmethacrylate[J]. Clin Orthop Relat Res, 2006, 445: 239-244.
[52]
Anagnostakos K, Kelm J, Grün S, et al. Antimicrobial properties and elution kinetics of linezolid-loaded hip spacers in vitro[J]. J Biomed Mater Res B Appl Biomater, 2008, 87(1): 173-178.
[53]
Ethell MT, Bennett RA, Brown MP, et al. In vitro elution of gentamicin, amikacin, and ceftiofur from polymethylmethacrylate and hydroxyapatite cement[J]. Vet Surg, 2000, 29(5): 375-382.
[54]
Bertazzoni Minelli E, Caveiari C, Benini A. Release of antibiotics from polymethylmethacrylate cement[J]. J Chemother, 2002, 14(5): 492-500.
[55]
Jackson J, Leung F, Duncan C, et al. The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength[J]. Drug Deliv Transl Res, 2011, 1(2): 121-131.
[56]
Mclaren AC, Mclaren SG, Smeltzer M. Xylitol and glycine fillers increase permeability of PMMA to enhance elution of daptomycin[J]. Clin Orthop Relat Res, 2006, 451: 25-28.
[57]
Mclaren AC, Nelson CL, Mclaren SG, et al. The effect of glycine filler on the elution rate of gentamicin from acrylic bone cement: a pilot study[J]. Clin Orthop Relat Res, 2004, (427): 25-27.
[58]
Weiss BD, Weiss EC, Haggard WO, et al. Optimized elution of daptomycin from polymethylmethacrylate beads[J]. Antimicrob Agents Chemother, 2009, 53(1): 264-266.
[59]
Parra-Ruíz FJ, González-Gómez A, Fernández-Gutiérrez M, et al. Development of advanced biantibiotic loaded bone cement spacers for arthroplasty associated infections[J]. Int J Pharm, 2017, 522(1/2): 11-20.
[60]
Rodriguez-Martinez JM, Ballesta S, Garcia I, et al. Activity and penetration of linezolid and vancomycin against staphylococcus epidermidis biofilms][J]. Enferm Infecc Microbiol Clin, 200725(7): 425-428.
[61]
Balato G, Roscetto E, Vollaro A, et al. Bacterial biofilm formation is variably inhibited by different formulations of antibiotic-loaded bone cement in vitro[J]. Knee Surg Sports Traumatol Arthrosc, 2019, 27(6): 1943-1952.
[62]
Holmberg A, Rasmussen M. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms[J]. Int J Antimicrob Agents, 2014, 44(1): 78-80.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 872-876.
[2] 姜珊, 李湘燕, 田硕涵, 温冰, 何睿, 齐心. 采用优化抗感染治疗模式改善糖尿病足感染预后的临床观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 398-403.
[3] 刘欢, 邢皓, 常正奇, 张记. 机械敏感性离子通道蛋白Piezo1在感染相关疾病中的研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 263-269.
[4] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[7] 邹永康, 石雍, 徐贤刚, 张帅民, 刘衍, 杨生鹏, 叶啟发, 陈根, 张毅. 肾移植术后手术切口米根霉感染伴菌血症一例并文献复习[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 289-292.
[8] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[9] 顾熙, 徐子宇, 周澍, 张吴楼, 张业鹏, 林昊, 刘宗航, 嵇振岭, 郑立锋. 腹股沟疝腹膜前间隙无张力修补术后补片感染10 例报道[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 665-669.
[10] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[11] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?